速递｜JAMA公布2025年度研究进展！GLP-1药物或首次显示可显著降低 HFpEF 患者死亡与住院风险

Core Viewpoint - The article discusses the emerging role of GLP-1 receptor agonists in managing heart failure with preserved ejection fraction (HFpEF), highlighting their potential cardiovascular benefits beyond weight loss [6][7]. Group 1: HFpEF and GLP-1 Research - HFpEF is becoming the most common type of heart failure globally, closely linked to rising obesity rates and the prevalence of type 2 diabetes [6]. - A recent study utilizing the Medicare claims database found that patients with obesity-related HFpEF and type 2 diabetes who started treatment with semaglutide or tirzepatide had over a 40% reduction in the risk of hospitalization for heart failure or all-cause mortality compared to those using sitagliptin [6][7]. - The study included over 58,000 patients, showcasing the significance of real-world evidence in complementing traditional clinical trials [7]. Group 2: Implications of GLP-1 Treatment - Despite previous beliefs that tirzepatide was superior for weight loss, it did not show a significant advantage in reducing heart failure hospitalization or mortality risk in this study, suggesting that the benefits of GLP-1 drugs in HFpEF may not solely depend on weight loss [7]. - The findings indicate that GLP-1 therapies are reshaping medical practice and public health, with potential implications for millions of HFpEF patients [7]. - The study reinforces the clinical value of GLP-1 treatments in managing cardiometabolic diseases, extending beyond previously established benefits [7].